| Listed site | cro | cro |
|---|
| Summary | Global preclinical CRO with 20+ years of experience supporting drug discovery through IND submission across small molecules and biologics, with 2,000+ scientists and facilities worldwide. | Global CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries. |
|---|
| Services | - Medicinal Chemistry
- Computational & In-Silico Drug Discovery
- High-Throughput Screening
- Target Identification & Validation
- Discovery Research
- Protein Engineering
- In Vitro Pharmacology
- In Vitro ADME / DMPK
- Safety Pharmacology
- Genetic Toxicology
- Preclinical In Vitro Studies
- Preclinical In Vivo Studies
- In Vivo Efficacy Models
- In Vivo PK / PD Studies
- GLP Toxicology
- Carcinogenicity Studies
- DART (Reproductive & Developmental Toxicology)
- Specialized & Large-Animal Models
- Bioanalysis
- LC-MS Bioanalysis (Small Molecule)
- Ligand-Binding Bioanalysis (Large Molecule)
- Immunogenicity Assays (ADA / NAb)
- Biomarker Assays
- Flow Cytometry Services
- Pathology & Histology Services
- Analytical Method Development & Validation
- ICH Stability Studies
- Translational Research
- Regulatory Affairs
| - Discovery Research
- Target Identification & Validation
- High-Throughput Screening
- Medicinal Chemistry
- Computational & In-Silico Drug Discovery
- Protein Engineering
- Preclinical In Vitro Studies
- In Vitro Pharmacology
- In Vitro ADME / DMPK
- Safety Pharmacology
- Genetic Toxicology
- Preclinical In Vivo Studies
- In Vivo Efficacy Models
- In Vivo PK / PD Studies
- GLP Toxicology
- Carcinogenicity Studies
- DART (Reproductive & Developmental Toxicology)
- Specialized & Large-Animal Models
- Bioanalysis
- LC-MS Bioanalysis (Small Molecule)
- Ligand-Binding Bioanalysis (Large Molecule)
- Immunogenicity Assays (ADA / NAb)
- Biomarker Assays
- Flow Cytometry Services
- Clinical Trial Services
- Phase I Clinical Trials
- Phase II Clinical Trials
- Phase III Clinical Trials
- Phase IV / Post-Marketing
- Data Management & eClinical
- Biostatistics & Statistical Programming
- Medical Writing
- Pharmacovigilance & Drug Safety
- Regulatory Affairs
- US FDA Regulatory Strategy
- EU EMA Regulatory Strategy
- Japan PMDA Regulatory Strategy
- China NMPA Regulatory Strategy
- Analytical Method Development & Validation
- ICH Stability Studies
- Translational Research
|
|---|
| Modalities | - Small Molecule
- Biologics (Monoclonal Antibodies)
- Biologics (Other)
- Antibody-Drug Conjugate (ADC)
- Oligonucleotide
- Peptide
| - Small Molecule
- Peptide
- Oligonucleotide
- Biologics (Monoclonal Antibodies)
- Biologics (Other)
- Antibody-Drug Conjugate (ADC)
- mRNA
- Cell Therapy
- Gene Therapy
- Vaccine
|
|---|
| Indications | - Oncology
- Immunology
- Neurology
| - Oncology
- Immunology
- Neurology
- Psychiatry
- Metabolic
- Cardiovascular
- Infectious Disease
- Rare Disease
- Respiratory
- Dermatology
- Ophthalmology
- Gastroenterology
- Nephrology
- Women's Health
|
|---|
| Locations | - Boston Center of Excellence, Watertown, Massachusetts, USA
- United Kingdom, Sandwich, Kent, United Kingdom
- Europe, Copenhagen, Denmark, Denmark
- Chengdu, Chengdu, China
- Jiangsu, Jiangsu, China
- Shanghai, Shanghai, China
- Malaysia, Malaysia, Malaysia
- Australia, Australia, Australia
- Copenhagen, Copenhagen, Denmark
- Malaysia, Malaysia
- Jiangsu, Jiangsu, China
- Australia, Australia
| - Headquarters, Shanghai, Pudong, China
- Global Operations, Asia, Europe, North America
|
|---|
| Certifications | - GLP · Identifier: GLP Compliant
- GMP · Identifier: cGMP Manufacturing / GMP Production
| Data not yet provided. |
|---|
| Reviews | Review summary appears after site-level review signal gate opens. | Review summary appears after site-level review signal gate opens. |
|---|